BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-2.58	-2.98	-1.6	-2.63	-0.36	0.75
Depreciation & Amortization	0.18	0.17	0.15	0.11	0.11	0.11
Asset Writedown & Restructuring Costs	-	-	0.04	0	-	-
Loss (Gain) From Sale of Investments	-0.02	0.07	-0.11	-0.31	0.07	0.03
Stock-Based Compensation	0.79	0.79	0.14	-	-	-
Provision & Write-off of Bad Debts	0.33	0.13	-0.8	0.95	0	0
Other Operating Activities	-0	-0.02	-0.04	-0.06	-0.11	-0.02
Change in Accounts Receivable	1.46	0.78	0.15	0.65	0.54	0.58
Change in Inventory	0.56	0.71	-0.25	-0.16	0.54	-0.35
Change in Accounts Payable	-1.06	-1.38	0.2	-0.38	-0.12	-1.18
Change in Unearned Revenue	-	-	-	-	-0.08	0.08
Change in Income Taxes	0.04	0.02	-0.04	-0.04	0.01	0.07
Change in Other Net Operating Assets	-0.55	-0.12	0.05	0.05	-0.07	-0.06
Operating Cash Flow	-0.85	-1.84	-2.09	-1.82	0.55	0.01
Operating Cash Flow Growth	-	-	-	-	5923.60%	-98.34%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-0.01	-0.04	-0.23	-0.15	-0.05	-0
Investment in Securities	1.02	1.02	0.58	-0.29	-0.51	-0.51
Other Investing Activities	0.38	-0.04	0.07	-1.35	0.12	0.02
Investing Cash Flow	1.39	0.94	0.42	-1.79	-0.45	-0.49

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Short-Term Debt Issued	-	0.03	0	0.01	-	-
Total Debt Issued	0.11	0.03	0	0.01	-	-
Short-Term Debt Repaid	-	-	-	-	-	-0
Long-Term Debt Repaid	-	-	-	-	-0.03	-0.03
Total Debt Repaid	-0	-	-	-	-0.03	-0.03
Net Debt Issued (Repaid)	0.11	0.03	0	0.01	-0.03	-0.03
Issuance of Common Stock	0.27	0.27	-	6.26	0.15	-
Other Financing Activities	-0	-0	-	-	-0.01	-
Financing Cash Flow	0.37	0.3	0	6.27	0.11	-0.03

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-0.06	0.19	0.04	-0.26	-0.21	-0.15
Net Cash Flow	0.85	-0.4	-1.63	2.4	-0.01	-0.66

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	-0.85	-1.88	-2.32	-1.97	0.5	0.01
Free Cash Flow Growth	-	-	-	-	8195.57%	-95.42%
Free Cash Flow Margin	-27.30%	-25.26%	-24.40%	-20.18%	4.55%	0.04%
Free Cash Flow Per Share	-0.39	-1.01	-1.30	-1.24	0.34	0.00
Levered Free Cash Flow	0.07	-0.85	-1.77	-0.57	0.73	-0.11
Unlevered Free Cash Flow	0.08	-0.84	-1.75	-0.56	0.73	-0.1

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	0	0.01	0.01	0.01	0.01	0.01
Cash Income Tax Paid	-	-0.03	0.04	0.07	0.17	0.23
Change in Working Capital	0.45	0.01	0.12	0.12	0.83	-0.86

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 15, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error